Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa

Bone Marrow Transplantation volume 30, pages 975–978 (2002)Cite this article

Abstract

Diffuse alveolar hemorrhage (DAH) is a potentially life-threatening pulmonary toxicity that occurs in 1–21% of patients following bone marrow transplantation. The syndrome is associated with a high mortality rate; and current treatment options are limited. Recombinant factor VIIa (rFVIIa, Novoseven) has recently been approved for the treatment of bleeding in patients with hemophilia A/B with inhibitors. A greater understanding of the mechanism by which rFVIIa restores hemostasis has recently become available; with in vitro evidence supporting that the thrombin burst achieved by rFVIIa is independent of the presence or binding to tissue factor. This insight has suggested a range of other potential clinical uses for the drug; including the setting of pulmonary hemorrhage. We review our experience with using rFVIIa for treatment of DAH in a patient with acute myelogenous leukemia following a matched unrelated donor bone marrow transplant. Boluses of 90 μg/kg rFVIIa were given every 3 h × 4 doses/day, concurrently with high-dose corticosteroids and maintenance of a platelet count >50 000/mm3. Rapid clinical and radiological improvement was noted within several doses of rFVIIa, with discontinuation of the drug after eight doses. However, the patient's clinical condition began to rapidly deteriorate following cessation of rVIIa, resulting in reinstitution of therapy 24 h later. The patient again exhibited rapid clinical improvement; and rFVIIa was continued for an additional 16 doses with no further evidence of pulmonary hemorrhage noted. No toxicity or adverse events were observed with rFVIIa treatment. Our experience indicates that rFVIIa may be an effective treatment option for DAH post bone marrow transplant; although further clinical studies are needed before recommendations can be made regarding off label use of rFVIIa in this clinical setting.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

References

  1. Lewis ID, Defor T, Weisdorf DJ . Increasing incidence of diffuse alveolar hemorrhage following allogeneic bone marrow transplantation: cryptic etiology and uncertain therapy Bone Marrow Transplant 2000 26: 539 543

    Article  CAS  Google Scholar 

  2. Robbins RA, Linder J, Stahl MG et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients Am J Med 1989 87: 511 518

    Article  CAS  Google Scholar 

  3. Mulder POM, Meinesz AF, de Vries EGE, Mulder NH . Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients Am J Med 1991 90: 278 280

    Article  CAS  Google Scholar 

  4. Agrusti C, Ramirez J, Picado C et al. Diffuse alveolar hemorrhage in allogeneic bone marrow transplantation. A postmortem study Am J Respir Crit Care Med 1995 15: 1006 1110

    Google Scholar 

  5. Huaringa AJ, Leyva FJ, Signes-Costa J et al. Bronchoalveolar lavage in the diagnosis of pulmonary complications of bone marrow transplantation patients Bone Marrow Transplant 2000 25: 975 980

    Article  CAS  Google Scholar 

  6. Huaringa AJ, Leyva FJ, Giralt SA et al. Outcome of bone marrow transplantation patients requiring mechanical ventilation Crit Care Med 2000 28: 1014 1017

    Article  CAS  Google Scholar 

  7. Witte RJ, Gurney JW, Robbins RA et al. Diffuse pulmonary alveolar hemorrhage after bone marrow transplantation: radiographic findings in 39 patients Am J Roentgenol 1991 157: 461 464

    Article  CAS  Google Scholar 

  8. Chan CK, Hyland RH, Hutcheon MA . Pulmonary complications following bone marrow transplantation Clin Chest Med 1990 11: 323 332

    CAS  Google Scholar 

  9. Raptis A, Mavroudis D, Suffredini AF et al. High-dose corticosteroid therapy for diffuse alveolar hemorrhage in alloeneic bone marrow stem cell transplant recipients Bone Marrow Transplant 1999 24: 879 883

    Article  CAS  Google Scholar 

  10. Toor AA, Slungaard A, Hedner U et al. Acquired factor VII deficiency in hematologic stem cell recipients Bone Marrow Transplant 2002 29: 403 408

    Article  CAS  Google Scholar 

  11. Blatt J, Gold SH, Monahan PE . Off label use of recombinant factor VIIa in patients following bone marrow transplantation Bone Marrow Transplant 2001 28: 405 407

    Article  CAS  Google Scholar 

  12. Telgt DS, Macik BG, McCord DM, Roberts HR . rFVIIa shortens PT and APTT: FX activation in absence of tissue factor Thromb Res 1989 56: 603 609

    Article  CAS  Google Scholar 

  13. Kristensen J, Killander A, Hippe E et al. Clinical experience with rFVIIa in patients with thrombocytopenia Homeostasis 1996 26: (Suppl. 1) 159 162

    CAS  Google Scholar 

  14. Poona MC, Castor O, Huth-Kuehne et al. Recombinant Factor VIIa in congenital platelet bleeding disorders Proc Am Soc Hematol 2000 96: 256a

    Google Scholar 

  15. Al Douri M, Shafi T, Al Khudairi DS et al. Effect of the administration of recombinant activated factor VII (rFVIIa; Novoseven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery Blood Coag Fibrinol 2000 11: (Suppl. 1) S121 S127

    Article  Google Scholar 

  16. McClellan SL, Komorowski RA, Farmer SG et al. Severe bleeding diathesis associated with invasive aspergillosis in transplant patients Transplantation 1985 39: 406 410

    Article  CAS  Google Scholar 

  17. Hedner U . Recombinant activated factor VII as a universal hemostatic agent Blood Coagul Finbrinolysis 1998 9: (Suppl.) S147 S152

    CAS  Google Scholar 

  18. White B, Martin M, Kelleher S et al. Successful use of recombinant FVIIa (Novoseven) in the management of pulmonary hemorrhage secondary to Aspergillus infection in a patient with leukemia and acquired factor VII deficiency Br J Haematol 1999 106: 254 255

    Article  CAS  Google Scholar 

  19. Meijer K, de Graaff W, Daenen S et al. Successful treatment of massive hemoptysis in acute leukemia with recombinant Factor VIIa Arch Int Med 2000 160: 2216 2217

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, Houston, TX, USA

    K Hicks, D Peng & JL Gajewski

Authors
  1. K Hicks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. JL Gajewski
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hicks, K., Peng, D. & Gajewski, J. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 30, 975–978 (2002). https://doi.org/10.1038/sj.bmt.1703731

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703731

Keywords

  • recombinant factor VIIa
  • bone marrow transplantation
  • pulmonary hemorrhage

This article is cited by

Search

Advanced search

Quick links